VSTM Q3 2025 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena

VSTMVerastem, Inc.

$388M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M

Gross Profit

$10M85.1% margin

Operating Income

-$41M-362.2% margin

Net Income

-$99M-876.3% margin

EPS (Diluted)

$-1.35

QoQ Revenue Growth

+426.1%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$177M

Total Liabilities

$192M

Stockholders' Equity

-$16M

Cash & Equivalents

$138M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$0	—
Gross Profit	$10M	$0	—
Operating Income	-$41M	-$37M	-10.0%
Net Income	-$99M	-$24M	-311.1%

Revenue Segments

Government rebates and other incentives

$2M76%

Trade discounts and allowances

$467,00018%

Returns

$165,0006%